APASL - 27th Annual Conference of the Asian Pacific Association for The Study of the Liver March 14-18 2018 Aerocity. New Delhi

Conference Reports for NATAP


APASL - 27th Annual Conference of the Asian Pacific Association for The Study of the Liver March 14-18 2018 Aerocity. New Delhi

	Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Japanese Adult Healthy Volunteers - (03/22/18) REAL-WORLD EFFECTIVENESS OF 12 WEEK ELBASVIR/GRAZOPREVIR (EBR-GZR) IN PATIENTS WITH GENOTYPE 1 (GT1) CHRONIC HEPATITIS C (HCV) AND CHRONIC KIDNEY DISEASE (CKD): RETROSPECTIVE DATA ANALYSES FROM THE TRIO NETWORK - (03/21/18) SAFETY AND EFFICACY OF ELBASVIR/GRAZOPREVIR IN ASIAN PARTICIPANTS WITH HEPATITIS C VIRUS INFECTION: AN INTEGRATED ANALYSIS OF DATA FROM 11 PHASE 2/3 TRIALS - (03/21/18) BURDEN OF COMORBIDITIES AND COMEDICATIONS IN A CHRONIC HCV POPULATION COMPARED WITH A NON-HCV POPULATION IN JAPAN BETWEEN 2015 AND 2016 - (03/21/18) Sofosbuvir/Velpatasvir Is Safe and Effective in a Phase 3 Study of Genotype 1-3 HCV-infected Russian and Swedish Patients - (03/21/18) Twelve Weeks of Ledipasvir/Sofosbuvir All-oral Regimen for Patients with Chronic Hepatitis C Genotype 2 Infection: Integrated Analysis of Three Clinical Studies - (03/21/18) Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B - (03/21/18)